Pharmakopsychiatrie
Neuro-Psychopharmakologie

Advances in Theoretical and
Clinical Research
Fortschritte in Theorie, Klinik
und Praxis

Herausgeber:
H. Coper, Berlin
M.-P. Engelmeier, Essen
A. M. Freedmann, New York
K. Heinrich, Düsseldorf
A. Herz, München
H. Hippius, München
P. Kielholz, Basel
B. Müller-Oerlinghausen, Berlin
K. Rickels, Philadelphia

Volume 9/1976

169 Abbildungen
in 198 Einzeldarstellungen
und 99 Tabellen

1976
Georg Thieme Verlag
Stuttgart

Geschützte Warennamen (Warenzeichen) werden *nicht* besonders kenntlich gemacht. Aus dem Fehlen eines solchen Hinweises kann also nicht geschlossen werden, daß es sich um einen freien Warennamen handelt.

Alle Rechte, insbesondere das Recht der Vervielfältigung und Verbreitung sowie der Übersetzung, vorbehalten. Kein Teil des Werkes darf in irgendeiner Form (durch Photokopie, Mikrofilm oder ein anderes Verfahren) ohne schriftliche Genehmigung des Verlages reproduziert oder unter Verwendung elektronischer Systeme verarbeitet, vervielfältigt oder verbreitet werden.

© Georg Thieme Verlag, Herdweg 63, Stuttgart, 1976 – Printed in Germany – Druck: Gulde-Druck, Tübingen

INHALTSVERZEICHNIS

Originalarbeiten

Åsberg, Maria: Treatment of Depression with Tricyclic Drugs – Pharmacokinetic and Pharmacodynamic Aspects 18

Bickel, P., A. Dittrich, J. Schoepf: Eine experimentelle Untersuchung zur bewußtseinsverändernden Wirkung von N,N-Dimethyltryptamin (DMT) 220

Bunney, E., L. Murphy: Neurobiological Considerations on the Mode of Action of Lithium Carbonate in the Treatment of Affective Disorders 142

Busch, H., E. Renfordt: Neue Strategien psychiatrischer Urteilsbildung durch Anwendung audiovisueller Technik. 2. Mitteilung: Zur Bedeutung verbaler und averbaler Informationen für die Beurteilung depressiver Patienten 235

Carlsson, A.: The Contribution of Drug Research to Investigating the Nature of Endogenous Depression 2

Coppen, A., R. Gupta, S. Montgomery, J. Bailey: A Double Blind Comparison of Lithium Carbonate and Ludiomil® in the Prophylaxis of Unipolar Affectiv Illness 94

Fieve, R.R., D.L. Dunner, T. Kumbaraci, F. Stallone: Lithium Carbonate Prophylaxis of Depression in Three Subtypes of Primary Affective Disorder 100

Fleischhauer, J.: Pimozid bei nicht psychotischen Alterspatienten mit Fehlverhalten im sozialen Umfeld. Eine offene Studie 332

Freyhan, F.A.: How Long should Prophylactics be Continued in Affective Disorders? 137

Ginestet, D., P. Peron-Magnan, P. Deniker: Critical Study of the Use of Long Acting Neuroleptics (Depot Neuroleptics) in France 183

Graw, P., W. Pühringer, Verena Lacoste, Anna Wirz-Justice, M. Gastpar: Intravenous L-5-Hydroxytryptophan in Normal Subjects: An Interdisciplinary Precursor Loading Study. Part II: Profile of psychotropic effects derived from protocols and psychometric investigations . . . 269

Günther, B., V. Hobi: Determinationsleistung und Drehsinnschwelle bei geringer Alkoholdosierung (um 0,5 ‰) unter Berücksichtigung habitueller und situativer Persönlichkeitsaspekte 323

Herrmann, W.M., R.C. Beach: Psychotropic Effects of Adrogens: A Review of Clinical Observations and New Human Experimental Findings 205

Hesbacher, P., P. Stepansky, W. Stepansky, K. Rickels: Psychotropic Drug Use in Family Practice . . . 50

Hobi, V., P.-Chr. Miest, R. Richter, E. Schwarz, L. Goldberg, D. Ladewig, G. Reggiani: Der zeitliche Verlauf der Alkoholwirkung in Skalen der Selbstbefindlichkeit 313

Hole, G.: Zum Entscheidungszwang in der begrifflich-nosologischen Zuordnung depressiver Syndrome und seiner Bedeutung für das therapeutische Konzept 295

Kielholz, P.: Long-term Therapy of Affective Disorders and Schizophrenia 93

Knorring, L., L. Oreland, C. Perris, Å. Wiberg: Evaluation of the Lithium RBC/Plasma Ratio as a Predictor of the Prophylactic Effect of Lithium Treatment in Affective Disorders 81

Kocher, R.: Die Behandlung chronischer Schmerzzustände mit Psychopharmaka 337

Kragh-Sørensen, P., C.E. Hansen, P.C. Baastrup, E.F. Hvidberg: Relationship between Antidepressant Effect and Plasma Level of Nortriptyline. Clinical Studies 27

Kragh-Sørensen, P., C.E. Hansen, P.C. Baastrup, E.F. Hvidberg: Therapeutic Control of Plasma Concentrations and Long-Term Effect of Nortriptyline in Recurrent Affective Disorders 178

Lacoste, Verena, Anna Wirz-Justice, P. Graw, W. Pühringer, M. Gastpar: Intravenous L-5.Hydroxytryptophan in Normal Subjects: An Interdisciplinary Precursor Loading Study. Part IV: Effects on body temperature and cardiovascular functions 289

Lader, M.: Monitoring Plasma Concentrations of Neuroleptics 170

Ladewig, D., P. Graw, P.-Chr. Miest, V. Hobi, Elisabeth Schwarz: Basler Drogen- und Alkoholfragebogen (BDA) 305

Lehrl, S., R. Straub, B. Straub: Ein Vergleich von Beurteilungsskalen und Leistungsverfahren für die Schweregradmessung zyklothymer Depressionen 247

Mandell, A.J., S. Knapp: A Neurobiological Model for the Symmetrical Prophylactic Action of Lithium in Bipolar Affective Disorder 116

Pach, J., W. Waniek: Vergleichende Untersuchung zum Tranquilizereffekt von Fluspirilene und Diazepam 61

Pare, C.M.B.: Unwanted Effects of Long-term Medication in Schizophrenia and Depression 187

Paykel, E.S., A. DiMascio, G.L. Klerman, B.A. Prusoff, M.M. Weissman: Maintenance Therapy of Depression 127

Perris, C.: Indications for Long-Term Pharmacological Treatment of Schizophrenic Syndromes 149

Pöldinger, W.: Principal Aspects of the Use of Placebos 302

Pühringer, W., Anna Wirz-Justice, P. Graw, Verena Lacoste, M. Gastpar: Intravenous L-5-Hydroxtryptophan in Normal Subjects: An Interdisciplinary Precursor Loading Study. Part I: Implications of reproducible mood elevation 260

Rafaelsen, O.J., E.T. Mellerup, R.W. Shapiro: Lithium in the Living Organism – Is an Integrated Hypothesis Feasible? 108

Renfordt, E., H. Busch: Neue Strategien psychiatrischer Urteilsbildung durch Anwendung audio-visueller Techniken. 1. Mitteilung: Verlaufsuntersuchung einer antidepressiven Therapie durch vergleichende und zeitblinde Auswertung von Fernsehaufnahmen 67

Rüther, E., R. Schilkrut, M. Ackenheil, E. Eben, H. Hippius: Clinical and Biochemical Parameters during Neuroleptic Treatment. I. Investigation with Haloperidol 33

Rybakowski, J., Z. Szajnerman: Lithium: Magnesium Relationship in Red Blood Cells during Lithium Prophylaxis 242

Sachar, E.J., H.P. Roffwarg, P.H. Gruen, N. Altmann, J. Sassin: Neuroendocrine Studies of Depressive Illness 11

Schildkraut, J.J., M. Roffman, P.J. Orsulak, A.F. Schatzberg, M.A. Kling, Th.G. Reigle: Effects of Short- and Long-Term Administration of Tricyclic Antidepressants and Lithium on Norepinephrine Turnover in Brain 193

Schilkrut, R., E. Rüther, M. Ackenheil, E. Eben, H. Hippius: Clinical and Biochemical Parameters during Neuroleptic Treatment. II. Antipsychotic Effect of Haloperidol in Patients with Chronic Organic Brain Damage 37

Schilkrut, R., E. Rüther, M. Ackenheil, E. Eben, H. Hippius: Clinical and Biochemical Parameters during Neuroleptic Treatment. III. Primitive Reflexes during Neuroleptic Treatment 43

Schooler, Nina, R., J. Levine, and the NIMH-PRB Collaborative Fluphenazine Study Group: The Initiation of Long-Term Pharmacotherapy in Schizophrenia: Dosage and Side Effect Comparisons Between Oral and Depot Fluphenazine 159

Simpson, G.M., M.H. Branchey, J.H. Lee, A. Voitashevsky, B. Zoubok: Lithium in Tardive Dyskinesia 76

Weindl, A., M.V. Sofroniew: Demonstration of Extrahypothalamic Peptide Secreting Neurons. A Morphologic Contribution to the Investigation of Psychotropic Effects of Neurohormones 226

Wirz-Justice, Anna, W. Pühringer, Verena Lacoste, P. Graw, M. Gastpar: Intravenous L-5-Hydroxytryptophan in Normal Subjects: An Interdisciplinary Precursor Loading Study. Part III: Neuroendocrinological and biochemical Changes 277

Mitteilungen 47, 85, 148, 203, 256

NAMENVERZEICHNIS

A
Ackenheil, M. 33, 37, 43
Altmann, N. 11
Åsberg, Maria 18

B
Baastrup, P.Chr. 27, 178
Bailey, J. 94
Beach, R.C. 205
Bickel, P. 220
Branchey, M.H. 76
Bunney, E. 142
Busch, H. 67, 235

C
Carlsson, A. 2
Coppen, A. 94

D
Deniker, P. 183
DiMascio, A. 127
Dittrich, A. 220
Dunner, D.L. 100

E
Eben, E. 33, 37, 43

F
Fieve, R.R. 100
Fleischhauer, J. 332
Freyhan, F.A. 137

G
Gastpar, M. 260, 269, 277, 289
Ginestet, D. 183
Goldberg, L. 313
Graw, P. 260, 269, 277, 289, 305
Gruen, P.H. 11
Günther, B. 323
Gupta, R. 94

H
Hansen, C.E. 27, 178
Herrmann, W.M. 205
Hesbacher, P. 50
Hippius, H. 33, 37, 43
Hobi, V. 305, 313, 323
Hole, G. 295
Hvidberg, E.F. 27, 178

K
Kielholz, P. 93, 259
Klerman, G.L. 127
Kling, M.A. 193
Knapp, S. 116
Knorring, L. 81
Kocher, R. 337
Kragh-Sørensen, P. 27, 178
Kumbaraci, T. 100

L
Lacoste, Verena 260, 269, 277, 289
Lader, M. 170
Ladewig, D. 305, 313
Lee, J.H. 76
Lehrl, S. 247
Levine, J. 159

M
Mandell, A.J. 116
Mellerup, E.T. 108
Miest, P.Chr. 305, 313
Montgomery, S. 94
Murphy, L. 142

O
Oreland, L. 81
Orsulak, P.J. 193

P
Pach, J. 61
Pare, C.M.B. 187
Paykel, E.S. 127
Perris, C. 81, 149
Peron-Magnan, P. 183
Pöldinger, W. 302
Prusoff, B.A. 127
Pühringer, W. 260, 269, 277, 289

R
Rafaelsen, O.J. 108
Reggiani, G. 313
Reigle, Th.G. 193
Renfordt, E. 67, 235
Richter, R. 313
Rickels, K. 50
Roffman, M. 193
Roffwarg, H.P. 11
Rüther, E. 33, 37, 43
Rybakowski, J. 242

S
Sachar, E.J. 11
Sassin, J. 11
Schatzberg, A.F. 193
Schildkraut, J.J. 193
Schilkrut, R. 33, 37, 43
Schoepf, J. 220
Schooler, Nina R. 159
Schwarz, Elisabeth 305, 313
Shapiro, R.W. 108
Simpson, G.M. 76
Sofroniew, M.V. 226
Stallone, F. 100
Stepansky, P. 50
Stepansky, W. 50
Straub, B. 247
Straub, R. 247
Szajnerman, Z. 242

V
Voitashevsky, A. 76

W
Waniek, W. 61
Weindl, A. 226
Weissman, M.M. 127
Wiberg, Ä. 81
Wirz-Justice, Anna 260, 269, 277, 289

Z
Zoubok, B. 76

Sachverzeichnis

A
Abhängigkeit
– Schweregrad 305, 306
acetylcholine 144
– receptors 145
Adaption 68
Addiction-Research-Center-Inventory 306
adenylate cyclase 144
adrenaline 3
adrenergic nerves 3
adrenocorticotropic hormone 11, 13
adrogenital syndrome 207
Äquivalenzanalyse 326
affective behaviour 266
– monoamine deficit hypothesis 266
affective disorder 81, 93ff, 112, 137, 142, 178, 200, 242, 260
– bipolar 100, 116, 242
– criteria of Feighner 101
– four-type-pump-defect model 108
– long therm therapy 93
– prophylactics 137, 138, 242
– recurrent 179
– subtypes of primary 100
– unipolar 81, 100, 242
affective illness 94, 97, 138
– remission 127
– serotonin-hypothesis 260
– unipolar 97, 139
Affective Morbidity Index 94, 96
affective psychosis 128
affective state 280
– neuroendocrinological function 280
aggression 217
Aggressivität 332, 335
Aktivierungskonzept, zweidimensionales 321
Aktivität, elektrodermale 313
alcohol 125
– chronical alcoholics 184
Alkohol 313ff, 324ff
– abhängigkeit 305ff
– gewohnheiten 323
allopurinol 286
Alternativdiagnostik 295, 297
Alternativtherapie 295
Alterspatienten 332
– Verhaltensstörungen 332
a-methyltyrosine 3, 6
aminergic transmission 117
amines 112
– amino acids 113
– reuptake 145
2-amino-4-hydroxy-6,7-dimethyl-5,6-7,8-tetra-hydropteridine 117
Amitriptylin 67, 68, 71, 73
Amitriptyline 4, 93, 127, 129, 130, 131, 132, 190ff
– side effect 133
ammonium groups 143
amphetamines 3, 51, 122, 124, 125, 213
AMP-System 34, 38, 67, 68, 73ff
amygdala 226, 230
Anafranil 337
analgesic agents 4
Analgetika 338
analysis of covariance 131, 132
androgenes 205ff
– antidepressive 209
– CNS effects 212
– deficiencies 205
– females 209
– sexuality 211
androstenedione 207
androsterone 207
anti-anxiety 51
anticholinergic drugs 156
– dependence 156
– psychotic reactions 156
antidepressant action 4
– psychomotor-activating effect 4
antidepressant agents 4, 51
antidepressant drugs 2, 53, 105, 216
– acute administration 193
– chronic 193
– bioavailability 20
– heart 190
– long-term treatment 178
– mode of action 2
– norepinephrine turnover 197
– pharmakodynamic 18
– pharmakogenic psychopathology 140
– pharmakokinetic 18
– side effects 97
– tetracyclic 68
– tremor 140
– tricyclic 2ff, 94, 100, 113, 127ff, 153, 178, 190ff, 217, 303, 337
– withdrawal 135
antidepressant effect 21, 27
antidepressive Therapie 67
– Verlaufsuntersuchung 67
antiepileptics 170
antigens 108
– membrane bound 108
antihistamines 5
– agents 4
antiparkinson drugs 155, 174
anti-parkinsonians 185
– agents 189
antipsychotic drugs 3
antipsychotic effects 3
apomorphine 14, 190
arginine 14
Atemfrequenz 314
– Bestimmungen 248
atomic absorption spectrophotometry 82
atrophy 46

atrophy, brain 46
– cortical 46
– diffuse 46
audio-visuelle Techniken 67, 235
Aufmerksamkeit 323
Augenbewegungen 314

B
BAK, Verlauf 324
Basler Drogen- und Alkoholfragebogen (BDA) 305
Beck Depression Inventory 94
Befindlichkeits-Skala 251
Benperidol 339
benserazide 260, 265, 277, 278, 284
– hPRL 284
– MAO-activity
benzodiazepines 174, 187ff, 265
– paradoxical effect 188
– tolerance 188
Benzodiazepinderivate 61
– Abhängigkeitsbildung 65
benztropine 159, 163
Berauschtheitsrating 314
Beschwerdelisten 221
Beurteilungsskalen 247, 253
Bildinformationen 236
biogenic amines 37, 142, 193
biperiden 34
bipolar 112
– affective psychosis 82
Blickkontaktraten 236
blood pressure 290
Blutalkoholkonzentrationskurve 313, 323
– Verlauf 327
body temperature 289
Boston Collaborative Drug Surveillance Program 187, 191
bouffées délirantes 184
bradycardia 292
brain amines 111
brief psychiatric rating scales 161, 185
bromamine 4
– 5-HT uptake 4
bromocriptine 190
butaperazine 173
Butyrophenonderivat 338
butyrophenone 154, 171, 189, 190

C
calcium 109ff, 143ff
– brain amines 111
carbidopa 265
carbohydrates 109, 112
– metabolism 109
cardiac 21
cardiotoxicity 23
carrier protein 144
catecholamines 14, 118, 144
– 1-5 HTP 283
cations, divalent 112
caudate 118
cell bodies 121
cell serotonergic 122
cell membrane 3, 144
central nervous system 20, 143, 144, 193
– transmission processes 242
cerebellum 196
cerebrospinal fluid (CSF) 18, 37ff, 230
chi-square 273
chlordesipramine 4
chlordiazepoxide 187ff
– dependence 188
chlorimipramine 4ff, 278ff, 337ff
chlorpheniramine, 5HT uptake, 4ff
chlorpromazine 3ff, 170ff
– anatomic effects 175
– catecholamine metabolism 3
– clinical response 172
– EEG 172
– eye changes 188
– metabolites 170
– N-oxide 171
– pharmacokinetics 171
– plasma concentration 172
– prolactin 175
– pupil size 172
circum-ventricular organs 229
climacteric syndrome 208
– male 208
clinical global measures 78
clonidine 14ff
cocaine 116ff
community psychiatry 127
copper sulfate 302
corpus striatum 196
cortex 196
corticosteroid 24
cortisol 11, 207, 277
– plasma 280
corticotropin releasing hormone, CRH 13ff
– secretion 14
Cronholm-Ottosson Rating Scale 28
– interrater reliability 28
cyclic peptides 143
– synthetic 143
cycloid psychotics 81ff, 151
cyclic-AMP 142, 143, 144

D
DAE-Skala 221
decarboxylase inhibition 277
– peripheral 277, 289
degenerative Veränderungen, Skelettsystem 338
dehydroepiandrosterone 207
Deming statistical analysis 104ff
11-deoxy-17-oxosteroids 206
Depottranquilizers 61
– depression 2ff
– acute 129
– amine deficiency 3
– androgen 209
– biochemical correlats 22
– chronic 105
– cortisol 11ff

depression, CSF biogenic amine metabolite level 18ff
– cyclothymical 247
– diagnostic inventory 28
– disorders 138, 193
– disturbance 132
– episode 105, 181
– evaluation 247
– 5 HIAA 20
– hormone levels 206
– illness 11ff, 104
– LH-secretion 14
– lithium carbonate prophylaxis 100ff
– long-therm-medication 187
– maintenance therapy 127ff
– manic 76, 100, 137, 145
– MAO aktivity 211
– neurotic 127ff
– non-psychotic 128
– noradrenergic activity 11
– outcome 128
– pathoneurochemistry 13
– pathophysiology 23
– performance test 247
– postmenopausal women 14
– psychogenic 295
– psychoneurotic 211
– psychopathology 24
– psychotic 128
– reactive 211
– recurrent episodes 142
– remission 128
– retardation 6
– scale 129
– symptomatology 13
– syndrome 266, 295
– unipolar 100, 128, 138, 181
– unwanted effects 187
depression endogenous 2ff, 23ff, 128, 266, 292ff
– diagnostic criteria 28
– 5 HIAA 266
– 5 HTP-treatment 266
– probenecid 266
– prophylactic long-therm-therapy 93
– prophylactic treatment 178
– therapeutic plasma range 31
Depressionen 247
– Ausprägung 235
– Beurteilung 239
– endogene 295
– endo-neurotische 296
– endo-psychogene 296
– endo-reaktive 296
– Leistungstests 248
– mehrschichtige 299
– psychogene 295
– psychopathometrische Leistungsergebnisse 254
– Schweregrad 254
– zyklothyme 247ff
Depressionsmessung 247ff
Depressions-Rating-Scale nach Hamilton 68
Depressionsskalen 249
depressives Syndrom 295
depressives, begrifflich-nosologische Zuordnung 295
– multifaktorielle Genese 300
– Psychodynamik 296
– schichtdiagnostisches Interpretationsmodell 300
– therapeutisches Konzept 295
Desipramine 4
desmethylchlorpromazine 171
desmethylimipramine 193ff
Determinationsgerät 323ff
Determinationsleistung 323ff
dexamethasone suppression tests 12
dexedrine 58
diabetes insipidus 143
– nephrogenic, central 143
Diagnosenschema 296
Diagnostik 298
– mehrdimensional 298
– multifaktoriell 298
– multikonditional 298
diazepam 187
– addiction 188
Diazepam 61ff
– Traumtätigkeit 65
digoxin 170
1-dihydroxyphenylalanine (1-dopa) 194
dopa 3ff, 261, 285
– central activity 3
– GH provocation 285
– temperature 290
N,N-Dimethyl-transferase 220
N-Dimethyltryptamin (DMT) 220
– Bewußtseinsveränderungen 220
diphenhydramine 5
Diskushernien 338
Dixeran 339
dopamine 3ff, 21, 33, 46, 144, 190, 284
– deficiency 33
– prolactin-release 264
– striatal 46, 285
dopamine neurons 4ff, 33
– receptorblockade 33ff
– transmitter re-uptake 4
dopaminergic pathway 175
double-blind studies 302
– investigation 303
doxepin 191
Drehsinnschwelle 323ff
Drehstuhl 325
Drogenabhängigkeit 305ff
drug overuse 50
dyskinesia 77
– late 156, 185
– reactions 34
– tardive 189
Dysthymie, endoreaktive 297

E

Einschätzungsskalen 248
electrical stimulation 111
electroconvulsive treatment 8
Elektroencephalography 24ff, 212, 248, 314
– disturbances 24

Elektroencephalography, photic driving 212
– sleep EEG 212
Elektrocardiography 314
electrolytes 109ff
– metabolism 109
electron microscopy 232
emotional problems 58ff
– classification of complaint 58
– illness severity 52ff
– race 58
– sex 58
Emotionen 236
endocytotic release 144
endomorph 299
epilepsy 150
Erlebnisreaktion, depressive 297
erythrocytes 111, 145, 244
– magnesium levels 242
estrogens 14
etiocholanolone 207
excitation 5
extrapyramidal effect 33
extrapyramidale Störungen 62, 332

F
Faktorenanalyse 305ff, 325
family meetings 130
family practice setting 51
feedback mechanisms 5
flame photometry 243
flashback 266
flicker fusion 215
Fluanxol 339
fluoride 144
fluphenazine 159ff, 339
– decanoate 159, 183ff
– dosage 159
– enanthate 183
– oral 159
– paranoid psychoses 184
– side effect 159
flupenthixol 171
– decanoate 183
Fluspirilene 61ff, 183
– Tranquilizereffekt 61
forebrain 112
– magnesium 112
Freiburger Persönlichkeits Inventar 62, 323ff
Fremdbeurteilungsskalen 247ff

G
GABA (gamma-amino butyric acid) 144, 189
GAD (glutamic acid decarboxylase) 189
galactorrhoea 189
gaschromatographic, essay 28, 170
Gerontopsychiatrie 332
Gewichtszunahme 62
glabellar reflex 43
Global 5-Point Affective Disorder Scale 102
globus pallidus 118
glucose 109
glycine 145
gonadal function 189
gonadectomy 16
gonadotropins 190
group therapy 130
growth hormone 11ff, 260, 277, 284
– responses 14
– insulin 14
– L-dopa 14
– menopause 14
– provocation
Grundstimmung, affektive 236

H
Habituationsversuche 313
Halluzinogen 221
Haloperidol 335ff
– effekt 248
– Tranquilizerwirkung 335
haloperidol 3, 33ff
– catecholamine metabolism 3
Hamburg-Wechsler-Intelligenztest für Erwachsene 249
Hamilton Rating Scale 101
Hautwiderstandsänderung 314
hebephrenic 173
hematochrit 82, 243
Herz 61, 314
– Rate 314
– Reaktion 314
– Sensation 61
hippocampal pyramidal cell 144
HL-A antigens 112
homosexual 207
Hopkins Symptom Checklist 52
hormone 212ff
– antidiuretic 226
– hypothalamic 226
– peptide 226
– pituitary 264, 284
– psychic function 226
– psychotropic effects 226
Huntington's Chorea 76, 150
homovanillic acid (HVA) 21ff
– concentrations 175
– CSF 40
hydroxychlorpromazine 170ff
5-hydroxyindoleacetic acid (5-HIAA) 18ff, 20ff, 261, 283
– blood 261
– cerebrospinal fluid 124, 261
– CSF 20, 24, 285
– urine 261
4-hydroxy-3-methoxyphenyl-glycol (MHPG) 20
5-hydroxytryptamine (5-HT) 2ff, 112ff
– biosynthetic 117
– limbic 112
– receptors 3
– synthesis 118
5-hydroxytryptophan, 5 HTP 6ff, 260, 263ff
– body sensations 271
– body temperature 289ff
– brain system lesion 263
– cardiovascular function 289

5-hydroxytryptophan, 5 HTP cortisol 277ff
– depressive patients 264
– diurnal 277ff
– dysphoric responses 271
– EEG-studies 263
– growth hormone 277
– hormon response 279
– infusions 261ff, 274
– monoaminergic system 283
– mood elevating effect 260ff
– motor activity 285
– organic brain syndrome 265
– peripheral decarboxylase inhibition 265
– PGO-waves 264
– pituitary hormone 261ff
– platelet 282
– psychic responses 262
– psychomotoric activity 269, 271
– psychotropic effects 269
– REM-parameters 266
– side-effects 261ff
– unspecific uptake 265
Hyperkinesie 332
Hypersalivation 335
hyperthermia 5
hypomanic episodes 102
hypnotics 303
hypophyseal portal system 190
hypothalamus 190ff, 226ff
– dysfunction 11ff
– neurohypophysical system 227ff
– releasing 284
hypothyroidism 143

I
illness classification 55
illness-treatment fit 53
imipramine 3ff, 96ff, 131ff, 190ff
– noradrenaline 3
immunocytochemistry 230
immunohistochemical procedure 227
I.M.P.S. (Lorr scale) 172
individual therapy 130
Informationen, averbale 235
inhibiting factors 284
Intelligenzniveau 247
Intelligenz-Struktur-Test 249
Interaktionschronograph 236
interactions of drugs 132
International Pilot Study of Schizophrenia 151
Interviewforschung 236
intoxications, chronic 150
ionophores, antibiotic 143
I.P.S.C. (self report) 130
isoleucine 113
Itemanalyse 305ff

K
Karzinom 338
Katatone 240
17-ketosteroid 206ff
kidney 143
Körperbaumaße 323
Körperbewegungen 236
kognitiv 240
Kombinationsbehandlung 337ff
Kontrastfehler 248
Konzentrationsfähigkeit 323
Kovarianzanalyse 324
Kraepelin-Schema 297

L
Laevomepromazin 339
lamina terminalis 226ff
L-aminoacid decarboxylase 6
Lebensalter 247
Leistungsmessungen 254
Leistungs-Prüf-System 249
Leistungsverfahren 247ff
– Buchstaben-Zahlen- und Wörterlesen 254
– Schweregradmessung 247
leucine 113
Librium 53ff
life events 134
limbic area 112
limbic system 3, 226, 230
neurosecretory cells 230
Lithium 76ff, 242ff
– adaptive process 124
– administration 193
– adrenergic neurons 144
– affective disorder 123
– antidepressant effect 144
– antimanic 123
– biogenic amines 108
– biological safety 139
– carbonate 94ff
– catecholamine synthesis 144
– cations 142, 242
– cellular process 142
– chloride 144
– cyclic AMP 143
– electromyographic recordings 140
– elderly 79
– electrolyte metabolism 180
– estimation 82
– glucose transport 109
– glycogen formation 109
– 5-hydroxyindoleatic acid 124
– living organism 108
– long-therm-treatment 108
– magnesium 108, 243
– mania 144
– manic-melancholic 108
– membrane function 142
– membrane stabilization 108
– mode of action 142
– molecular level 142
– molecular sites 142
– norepinephrine 144, 193ff
– pharmacogenic complications 139
– phosphate uptake 109
– physical chemistry 142
– plasma 81

Lithium, polyuria 143
– potassium 143
– prophylactic 81ff
– RBC-index 244
– receptors 142ff
– red blood cells 81, 242
– responders 245
– serumphosphate 109
– sodium 143
– sulfate 199
– therapeutic failures
– therapeutic goals 139
– toxic effects 140
– tremor 140
liver 171
long acting neuroleptics 183
long therm pharmacological treatment 149ff
– indications 149
– schizophrenic syndromes 149
long therm pharmacotherapy 149ff
– consolidating 149
– maintenance 149
– relapse 149
LRF 14
Ludiomil® 94
lumbar, puncture 34
luteinizing hormone releasing hormone (LRH) 226

M
magnesium 109ff, 242
maintenance treatment 127
major tranquillisers 170
mania 76ff
manic-depressive 138ff
– disease 178
– episodes 138
– patient 200
manic-melancholic disorders 108
– membrane transport deficiencies 108
– pump deficiencies 113
manic-melancholic patients 108
– diurnal variation 109
manic-melancholic states 112
maprotiline 93
– prophylactic effect 94
mass fragmentography 24
Maudsley Personality Inventory 323ff
median eminence 230, 284
Mehrdimensionaler Depressionstest 251
Mehrfachwahl-Wortschatz-Test 251
melancholia 113, 227
membrane 108
– dysfunction 108
– function 112
– stabilization 111
– structure 112
memory 226, 232
menopause 208
Mental Performance 217
Mental Status Evaluation Record 161
mesterolone 209ff
– psychoneurotic 211
– sleep stages 213
metabolic balance studies 109
3-methoxy-4-hydroxyphenylglycol-sulfate (MHPG) 196ff
Mianserin 67ff
– Depressivität 73
Michigan-Alcoholism-Test 305
midbrain 117ff
– lateral 122
– raphe 117
– serotonergic cell bodies 117
Mildefehler 248
100 mmLine 273
monoamines 2ff, 284
– availability 2, 8
– brain 2, 284
– deleption 2
– oxidase inhibitors 2
– precursors 2, 8
monoamine metabolites 6, 284
– cerebrospinal fluid 6
monoamine oxidase inhibitor 5, 100, 209ff
– activity 281
– l-5HTP 281
– platelet 277
monoamine receptor 8
– sensitivity 8
monoaminergic neurons 20
– pharmacodynamic aspects 22
– uptake inhibition 20
monoaminergic systems 289
Mononeuritis multiplex 338
Mood Scales 130, 273
Motorik 323
morphine 122, 125

N
nerve endings 121, 145
– enzyme activity 121
nerve terminals 116
neuroendocrinology 226
– function 11
neurohormones 226
neurohypophysis 226
Neuroleptika 65, 332ff
– Verhaltensstörungen 332
neuroleptic drugs 45, 137
– decompensation phenomenon 45
neuroleptics 46ff, 137, 188, 303ff
– antipsychotic efficiency 33
– biochemical pharmacology 178
– clinical pharmacology 170
– combination 155
– concentrations 175
– depot 155, 160
– depressive reactions 156
– dopamine defieciency 33
– dopaminergic neurons 46
– dosage 155
– effects 37, 154
– enzymeinduction 156
– extrapyramidal action 33, 153
– frequency of utilisation 184
– indications 183

neuroleptics, interactions 170
– long-acting 156
– metabolic pattern 170
– pharmacogenic psychopathology 140
– pharmacokinetic 153ff
– plasma concentration 170ff
– plasma levels 153
– relapses 185
– side effects 154
– suicide 156
– tardive dyskinesia 189
– target symptoms 154
neuroleptic therapy 44
– extrapyramidal side effects 44
– glabellar reflex 44
neuroleptic treatment 33ff, 153
Neurological Rating Scale 78
Neuropathien 338
neurophysin 226ff
neurons 194
– extrahypothalamic 226
– peptide secreting 226
– presynaptic 194
neuro-psychopharmacology 230
Neurosen 297
neurotransmitters 111, 123, 144
– metabolism 142
New York State Psychiatric Institute Lithium Clinic 100
N-methyl-protriptyline 4
noradrenaline 2ff, 112, 266ff
– psychomotor activity 2
– secondary amines 4
– tertiary amines 4
– uptake 22
norepinephrine 144ff, 198
– biosynthesis 194
– extraneuronal 194f
– metabolism 193
– reptake 145
– uptake 193ff
nortryptiline 4, 18ff, 172ff
– plasma levels 21, 180
– side-effects 21
– therapeutic effect 180
Nosie 185
Nozinan 337
nuclei 226
– paraventricular 230
– suprachiasmatic 226
– supraoptik 230
– triangular 226ff

O
ocular accomodation 21
oestrogens 284
ogliopeptides 226
Ogliophrenie 335
opiate 145
oral mechanisms 44
oral responses 43
Organbeschwerden 64
– funktionelle 61
organic brain damage 37, 43
organum vasculosum 227
Orientierungsreaktion 313
orphenadrine 174
orthostatic reaction 290
Overall Judgement of Psychopathology 52ff
oxazepam 187ff

P
palmomental reflex 43
paranoia 184
– patients 173
paranoid-hallucinatory syndrome 33
paraventricular nuclei 226
Parkinson 240
parkinsonism 33ff
– post-encephalitic 43
– secondary manifestations 43
parkinson's disease 2, 43
– L-dopa 3
Pauli-Test 214
p-chlorophenylalanine 6ff
Pearson product moment correlation 163
pentobarbital 226
peptides 229
perphenazine enanthate 183
Persönlichkeitsmerkmale 314
– habituelle 323
– situative 323
Persönlichkeitstest 61
personality characteristics 218
personality structure 302
Peru-Balsam 302
pharmacodynamic 18
– profile 23
pharmacokinetic 18, 293
pharmacopsychiatry 93
pharmacotherapy 59, 187
– long therm 155
Pharmakotherapie 68, 295
– antidepressive 68
phenobarbital 53
phenobarbitone 174ff
phenothiazines 123ff, 171ff
– piperazine subgroup 153
phenylketonuria 293
phosphate 109
Pimozid 335
– affektive Störungen 335
pimozide 171, 332
– metabolism 171
piportil L4 183
piportil M2 183
pipothiazine 183
– deficitary psychoses 184
– palmitate 183
– undecylenate 183
pituitary hormones 11
Placebos 302
plasma 170
– concentration 170, 178
– protein binding 170, 174
Plexus brachialis 338

Plexus lumbosacralis 338
polyethers 143
– cropolycyclic 143
Polyneuropathien 338
pons-medulla 196
porphyrinopathies 150
postsynaptic receptor sites 2, 20
potassium 108ff, 143ff, 242
Präcoxgefühl 240
Priadel 94
primitive reflexes 43
private practice research group 52
Produkt-Moment-Korrelationskoeffizient 251
progestin 207
prolactin 175, 264ff
– circadian rhythm 189
– inhibitory factor 190
Propericiazin 339
prophylaxis 137
prostaglandin E1 144
Protriptyline 4
psychiatric treatment 127
Psychiatrie, nachkraepelinsche 300
psychiatrist's global evaluation 185
psychoactive drugs 137
psychochemistry 112
psychodynamics 302
psychoexperimental test battery 214
psychomotor function 217
psychomotor seizure 263
psychoneurotic disorders 59
psychopathic disorders 184
Psychopathien 333
Psychopathologie, klassische 297
psychopathology 34, 137
– schizophrenic 161
Psychopharmaka 67, 113, 337
– Schmerzzustände 337
– Zeitwirkprofil 67
psychopharmacology 2, 112, 127
psychophysiologische Verfassung 323
psychose hallucinatoire chronique 184
Psychosen 297
– affektive 297
– endomorphe 299
– reaktiv depressive 297
psychoses 150
– acute 184
– chronical 184
– cycloid 150
– manic-depressive 151
– reactive 150
– schizo-affective 150
psychosis 78, 185
– manic-depressive 244
– toxic 80
psychosocial adjustment 137
psychosomatic medicine 303
Psychostimulants 216
Psychotherapie 295
psychotherapy 129ff
– social adjustment 132
psychotic patients 33
psychotropic drugs 50ff, 123, 302
– age 55
– dispensing patterns 50
– distribution 50
– emotional problems 51
– family practice 50
– females 54
– males 54
– marital status 55
– production 50
– race 55
– side-effects 153
– social class 55
– sudden death 153
psychotropic substances 205
pteridine cofactor 117
pulse rate 290
Pulsfrequenzbestimmungen 248
pupil size 175
putamen 118

R
radioimmunoassay 16, 233, 284
raphe 117
raphe neurons 116
Rauchgewohnheiten 323
RBC-plasma 82
receptors 144, 194
– dopamine 144
– norepinephrine 144, 194
recipavrin 5
red blood cells 81, 242
Reiz, akustischer 313
Reliabilitätsbestimmung 306ff
reserpine 2, 7ff, 111, 197
– extrapyramidal actions 3
– syndrome 3

S
Scree-Test 308
sedatives 51ff
self-assessment 270
Selbstbefindlichkeit 313ff
Selbstbeurteilungsskalen 247
Selbsteinschätzungsverfahren 61
self report rating scales 130ff
semantisch 240
septum 117, 226
serotonergic neurons 119
serotonergic transmission 124
serotonin 11ff, 112ff, 260ff
– aggressive behaviour 24
– pituitary hormone 280
– turnover 23ff
– uptake 20
serotoninergic mechanisms 285
– central 289
– growth hormone 285
– sex specific factors 289
– thermoregulation 289
serotoninergic systems 264

sexuality 217
Simpson Scale 34ff
SKAS-Hampel 62ff, 273, 325
sleep disturbance 11
sleep-wake cycle 12
smallpox, immunization 303
social adjustment 133
sodium 81, 242ff
– chloride 118
– extra-, intracellular 145
Sozialverhalten 332, 335
Spannungskopfschmerzen 61
spectrophotofluorimetric methods 24, 243
Sprachäußerungen, depressive 240
Sprague-Dawley rats 118
suicide attempts 23, 128
Surmontil 337
synapses 145
synaptic effect 145
synaptosome 145

Sch
Schätzskala 74
– averbale Faktoren 74
Schichtdiagnose 297
schizophrenia
– adrenal cortical activity 207
– chronic 152, 185, 207
– good prognosis 150
– hebephrenic 184
– latent 151
– long therm therapy 93, 159, 187
– non regressive 151
– paranoid 184
– pseudoneurotic 151
– pseudo-psychopathic 151
– recurrent 150
– remitting 150
– simple 173
– tricyclic antidepressive 174
– unwanted effects 187
schizophrenia-like syndromes 150
– epilepsy 150
schizophrenic disorders 150
– etiopathogenesis 150
– prognosis 150
– symptomatology 150
schizophrenic syndromes 149ff
– long term pharmacological treatment 149
Schizophrenieforschung 220
– chemische 220
Schlafstörungen 62
Schmerzdistanzierung 340
Schmerzzustände 337ff
Schneiderian first rank symptomes 161
Schulter-Beckenindex 325
Schwierigkeitsschärfeindex 307

St
Stimmung 275, 323, 328ff
– Labilität 335
Stimmungsverlauf 326
striate 122
– synaptosomes 122
striate cortex 116ff
Striatum 3
– dopamine stores 3
stress 11
strychnine 226
student's t-test 82

T
Tagesmüdigkeit 62
tardive dyskinesia 76
– rating scale 78
Testhalbierungs-Reliabilität 305
Testkonstruktion 305ff
testosterone 206ff
– EEG 213
– mental performance tests 214
Tests 248
– Gestaltungstests 248
– projektive 248
– psychopathol. Leistungstests 248
– Wahltests 248
thalamus 226
thiaxanthene 154
thioridazine 93, 173, 189ff
– eye changes 188
– retinal pigmentation 189
thioxanthenes 171
thymoleptics 266
Thymoleptika 337
thyroglobulin 144
thyroid 143
thyrotropin releasing hormone 226
thyroxin 144
Tofranil 337
Tonbandprotokoll 236
Toninformationen 236
Tonstärkeeinschätzung 314
tranquillizers 51ff
transmitter 5, 116, 121
– metabolic breakdown 5
– metabolites 18
– synthesis 5
transport disturbances 113
Traumtätigkeit 62
treatment, maintenance 190
tremor 79
Trennschärfeindex 307
tricyclic drugs 2ff, 123, 266ff
– antidepressants 19, 100ff
– bioavailability 20
– long term treatment 138, 178
– pharmacodynamic 18
– pharmacokinetic 18
– plasma concentrations 19
– suicidal risk 93
trifluor piperidine phenothiazine 183
Trigeminusneuralgien 338
Trimeprimin 337ff
trihydroxybenzylhydrazine 286
Trömgren-Index 325

Tryptamin 220
tryptophan 6ff, 113ff, 260ff
– bound 278
– depression 6
– exogenous 118
– free 113, 278
– plasma free 282
– total 113
tryptophan hydroxylase 6, 116ff
– activity 124
– median raphe 116
– synthesis 120
– turnover 120
tryptophan pyrrolase 286
tyramine pressor test 20
tyrosine 118ff, 194
– uptake
tyrosine hydroxylase 3, 197

U
Umfeld, soziales 332
unipolar affective illness 94
– prophylaxis 94

V
valine 113
Varianzanalyse 324
vasopressin 143, 226ff
– ADH 143
Verdachtsdiagnose 240
Verhalten 236
– averbal 236
– quantifiziert 236
Verhaltensmuster, averbal 74
Verhaltensstörungen 335
Verstimmtheit 61
– depressive 61
hypochondrische 61
vesicles 144
– intracellular 144
Vestibularsystem 325
Vierfelder-Test 71
vision, blurred 21
vitalisiert 299

W
Wahrnehmungsprozesse 323
Webster scale 34ff
Weltgesundheitsorganisation WHO 306
White-test 291
Wilcoxon-Test 62
Wirkungslatenz 69

X Y
χ^2-Test 70, 82
Yates correction 82

Z
Zeit-Wirkungsprofil 68
von Zerssen Scale 221, 251